Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
Inventors
Assignees
Publication Number
US-9439855-B2
Publication Date
2016-09-13
Expiration Date
2028-12-16
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
A pharmaceutical composition comprising an amphiphilic emulsifier, a polar liquid carrier and, optionally, a lipid component. The amphiphilic emulsifier form free-moving, optionally lipid-carrying, micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure and correct hypovolemia.
Core Innovation
The invention relates to a pharmaceutical composition comprising an amphiphilic emulsifier and a polar liquid carrier, wherein the amphiphilic emulsifier forms free-moving micelles with a lipophilic core in the carrier. The pharmaceutical composition is notable for being free of hemoglobin and fluorocarbon. Optionally, a lipid component may be present to fill the hydrophobic space of the micelles. This unique composition is employed for treating conditions related to lack of blood supply, and also for raising blood pressure and correcting hypovolemia.
The problem being addressed is the inadequacy of existing treatments for shock due to blood loss, vasodilation, or dehydration, which fail to restore and maintain tissue perfusion effectively. Current resuscitation fluids, such as crystalloids and colloid-containing solutions (like HETASTARCH™), present limitations and complications such as rapid diffusion, enhanced bleeding, and increased risks of renal failure and mortality. Overreliance on vasoconstrictors leads to reduced tissue perfusion and tissue necrosis. There is a need for a low-cost therapeutic volume expander that is capable of effectively delivering oxygen and nutrients to tissues while minimizing inflammatory responses.
The core innovation provides a solution by utilizing amphiphilic emulsifiers that form micelles in a polar carrier, enabling the transport of lipophilic gases such as oxygen and nitric oxide to body tissues. This pharmaceutical composition can exert an osmotic force, absorb harmful mediators of tissue injury, and can act as a blood volume expander without the drawbacks associated with hemoglobin or perfluorocarbon-based oxygen carriers. The invention further describes administration methods and various optional additives for customizing the composition to address specific clinical needs.
Claims Coverage
There is one independent claim in the patent, from which several dependent claims specify additional features. The independent claim covers the main inventive features of the method and composition.
Method for raising blood pressure using a micelle-forming pharmaceutical composition
A method for raising the blood pressure in a subject with hypovolemia by administering a pharmaceutical composition that comprises: - An amphiphilic emulsifier - A polar liquid carrier The amphiphilic emulsifier forms free-moving micelles or liposomes with a lipophilic core in the polar liquid carrier. The micelles or liposomes have an average diameter in the range of 2 to 300 nm. The pharmaceutical composition is free of hemoglobin and fluorocarbon.
The claim coverage centers on the use of a specific micelle- or liposome-based pharmaceutical composition, free of hemoglobin and fluorocarbon, for raising blood pressure in hypovolemic subjects. The main inventive feature is the combination of amphiphilic emulsifier and polar liquid carrier forming micelles or liposomes within a defined size range.
Stated Advantages
Enables oxygen and nutrient delivery to tissues in the absence of hemoglobin or fluorocarbon.
Provides a volume expander that can raise blood pressure and correct hypovolemia.
Minimizes complications associated with current resuscitation fluids, such as enhanced bleeding, renal failure, and mortality.
Exerts osmotic force and absorbs harmful inflammatory mediators, improving tissue protection during shock states.
Can be customized with additives (e.g., anti-inflammatory agents, histidine, amino acids) for enhanced therapeutic effects.
Documented Applications
Treatment of conditions related to lack of blood supply, including hypovolemia, hemorrhagic shock, and severe hemorrhagic shock.
Raising blood pressure in subjects with hypovolemia.
Use as a blood volume expander.
Oxygenation of patients whose lungs are unable to absorb oxygen, serving as an alternative to extracorporeal membrane oxygenation (ECMO).
Exchange transfusion and whole circulation perfusion to wash out blood containing infectious, cancerous, or toxic agents.
Absorption and removal of excess nitric oxide in septic shock.
Administration of nitric oxide-loaded compositions to treat vasoconstriction and hypertension including Raynaud's disease, Prinzmetal's angina, cerebral vasospasm, atherosclerosis, and sickle cell crisis.
Preservation of organs by perfusion during transplantation.
Treatment of seizure and neuronal injuries, including ischemic stroke and traumatic brain injury, by delivery of xenon/argon through the composition.
Diagnostic use by analyzing absorption of lipophilic moieties generated in disease states.
Interested in licensing this patent?